Abstract
Recently, there have been a few reports of rituximab (RTX)-induced Crohn's disease, but there is no literature available on successful long-term treatment and the clinical outcome of this condition. We retrospectively analyzed the clinical data of a rare case of Crohn's disease induced by RTX administered as induction and prolonged maintenance therapy of a follicular lymphoma, diagnosed synchronously with a gastric signet ring cells carcinoma, treated at our hospital.
Keywords:
Crohn’s disease; Gastric signet ring cells carcinoma; Lymphoma; Rituximab.
MeSH terms
-
Anti-Inflammatory Agents / therapeutic use*
-
Antineoplastic Agents, Immunological / adverse effects*
-
Budesonide / therapeutic use
-
Carcinoma, Signet Ring Cell / diagnosis
-
Carcinoma, Signet Ring Cell / drug therapy
-
Carcinoma, Signet Ring Cell / immunology
-
Crohn Disease / chemically induced
-
Crohn Disease / diagnosis
-
Crohn Disease / drug therapy
-
Crohn Disease / immunology*
-
Drug Therapy, Combination / methods
-
Humans
-
Induction Chemotherapy / adverse effects
-
Induction Chemotherapy / methods
-
Lymphoma, Follicular / diagnosis
-
Lymphoma, Follicular / drug therapy
-
Lymphoma, Follicular / immunology
-
Maintenance Chemotherapy / adverse effects
-
Maintenance Chemotherapy / methods
-
Male
-
Mesalamine / therapeutic use
-
Middle Aged
-
Neoplasms, Multiple Primary / diagnosis
-
Neoplasms, Multiple Primary / drug therapy
-
Neoplasms, Multiple Primary / immunology
-
Rituximab / adverse effects*
-
Stomach Neoplasms / drug therapy
-
Stomach Neoplasms / immunology
-
Treatment Outcome
Substances
-
Anti-Inflammatory Agents
-
Antineoplastic Agents, Immunological
-
Rituximab
-
Mesalamine
-
Budesonide